Medical devices

Global Hearing-Aid Devices (Hearing Aid Devices v/s Hearing Implants) Market, Competition Forecast & Opportunities, 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Audiology, Nervous system, Hearing loss, Otorhinolaryngology, Otology, Hearing, Deafness, Hearing aid, Sensorineural hearing loss, SoundBite Hearing System, Congenital hearing loss

The "Global Hearing-Aid Devices Market, By Type (Hearing Aid Devices v/s Hearing Implants), By Type of Hearing Loss (Sensorineural v/s Conductive), By Product Type, By Technology Type, By Patient Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Hearing-Aid Devices Market, By Type (Hearing Aid Devices v/s Hearing Implants), By Type of Hearing Loss (Sensorineural v/s Conductive), By Product Type, By Technology Type, By Patient Type, By Distribution Channel, By Region, Competition Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Global Hearing-aid Devices Market stood at USD15.86 billion in value terms in 2020 and is forecast to grow at CAGR of 5.49% to reach USD21.61 billion by 2026.
  • Moreover, growing trend for customized implants is also a major factor that is driving the hearing-aid devices market.
  • The Global Hearing-aid Devices Market is categorized by type, type of hearing loss, product type, technology type, patient type, distribution channel, and regional distribution.

Canon Medical to Present at HIMSS 2021 August 9th-12th

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Hospitals, Philanthropy, Practice Management, Other Health, Radiology, General Health, Fund Raising, Health, Oncology, Health informatics, Articles, Technology, Health, Healthcare Information and Management Systems Society, Telehealth, Canon Inc., Canon law of the Catholic Church, eHealth

For the first time ever, Vital Images will present at the HIMSS conference as Canon Medical Group.

Key Points: 
  • For the first time ever, Vital Images will present at the HIMSS conference as Canon Medical Group.
  • HIMSS attendees, in-person and digital, can engage in discussions about innovation, enterprise imaging, telehealth, remote reading, and more.
  • Canon Medical is calling on customers to be an innovative force within their organization.
  • At Canon Medical, we work hand in hand with our partners our medical, academic and research community.

Global Industry Executive Aster Angagaw Joins PAVmed Subsidiary Lucid Diagnostics’ Board of Directors

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, General Health, Health, Medical devices, Articles, Lucid, Board of directors, Aster, NASDAQ, Business

PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. (Lucid).

Key Points: 
  • PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical technology company, today announced that prominent global industry executive Aster Angagaw has joined the Board of Directors of its majority owned subsidiary Lucid Diagnostics Inc. (Lucid).
  • View the full release here: https://www.businesswire.com/news/home/20210803005717/en/
    Global industry executive Aster Angagaw joins PAVmed's subsidiary Lucid Diagnostics Board of Directors (Photo: Business Wire)
    I am delighted to welcome Aster Angagaw to Lucids Board of Directors, said Lishan Aklog M.D., PAVmeds Chairman and Chief Executive Officer and Lucids Executive Chairman.
  • She brings decades of business experience as a chief executive, global transformation leader, and public company director, with deep longstanding roots in the global healthcare sector.
  • For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com , follow Lucid on Twitter , and connect with Lucid on LinkedIn .

Australia Clear Aligners Markets 2021-2028 by Age (Adults, Teenage), End Use (Hospitals, Stand Alone Practices, Group Practices), Distribution Channel (Online, Offline) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Materials, Dental equipment, Orthodontic appliances, Goods economics), Plastics, Matter, Clear aligners, Dental braces, Copolyester, Polycarbonate

The "Australia Clear Aligners Market Size, Share & Trends Analysis Report by Age (Adults, Teenage), by End Use (Hospitals, Stand Alone Practices, Group Practices), by Distribution Channel (Online, Offline), and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Australia Clear Aligners Market Size, Share & Trends Analysis Report by Age (Adults, Teenage), by End Use (Hospitals, Stand Alone Practices, Group Practices), by Distribution Channel (Online, Offline), and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Australia clear aligners market size is expected to reach USD 534.3 million by 2028.
  • The market is expected to expand at a CAGR of 28.7% from 2021 to 2028.
  • Clear aligners are invisible and discreet braces developed from thermoformed materials like copolyester or polycarbonate plastic and CAD 3D printing technology, acting as an alternative to traditional braces.

Neonatal Phototherapy Market Insights, Competitive Landscape and Market Forecast Report 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 3, 2021
Baby, Maternity, Health, Consumer, Medical devices, Neonatology, Clinical medicine, Medicine, Psoriasis, Medical specialties, Circadian rhythm, Light therapy, Treatment of bipolar disorder, Hepatology

What was the neonatal phototherapy market share (%) distribution in 2018 and how it will look like in 2026?

Key Points: 
  • What was the neonatal phototherapy market share (%) distribution in 2018 and how it will look like in 2026?
  • What will be the neonatal phototherapy market growth till 2026 and what will be the resultant market size in the year 2026?
  • What are the neonatal phototherapy available in the market, their product description, regulatory milestones, product development activities, research and development activities etc.?
  • What are the 7MM countries historical and forecasted market of neonatal phototherapy?

Kestra Medical Technologies Receives FDA Premarket Approval for ASSURE Wearable Cardioverter Defibrillator (WCD)

Retrieved on: 
Tuesday, August 3, 2021
FDA, Health, Cardiology, Medical devices, Cardiac electrophysiology, Branches of biology, Medical technology, Human–computer interaction, Cardiology, Medical equipment, Wearable cardioverter defibrillator, WCD, Automated external defibrillator, Medical device, Wearable technology, Cardiac arrest

Kestra Medical Technologies, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) Premarket Approval for the ASSURE Wearable Cardioverter Defibrillator (WCD) system.

Key Points: 
  • Kestra Medical Technologies, Inc. announced today that the company has received U.S. Food and Drug Administration (FDA) Premarket Approval for the ASSURE Wearable Cardioverter Defibrillator (WCD) system.
  • The ASSURE WCD system represents the next generation of monitoring and therapy to protect patients at risk of Sudden Cardiac Death (SCD).
  • The system includes a modern, comfortable wearable device with integrated sensors, a cardiac rhythm monitor and miniaturized automated external defibrillator.
  • Kestra Medical Technologies, Inc. is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile.

Veranex Announces Acquisition of Experien Group

Retrieved on: 
Tuesday, August 3, 2021
Technology, Research, Medical devices, Clinical trials, Biotechnology, Health, Pharmaceutical, Data management, Science, Zimmer Biomet Robotics, Medtech

Veranex , the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.

Key Points: 
  • Veranex , the first concept-to-commercialization global service provider dedicated to the medtech industry, today announced the acquisition of Experien Group, a leading provider of a full range of regulatory, quality, and clinical consulting services to medtech companies.
  • We are excited to welcome Experien Group to Veranex, said David Dockhorn , CEO of Veranex.
  • With this acquisition, Veranex adds the premier provider of regulatory, quality, and clinical consulting services to medtech companies.
  • Experien Group adds another layer of value and medtech insight to Veranex, said Veranex Executive Chairman Pat Donnelly .

Titan Medical to Report Second Quarter 2021 Financial Results on August 11, 2021

Retrieved on: 
Tuesday, August 3, 2021
General Health, Surgery, Medical devices, Other Health, Health, Lemieux, Webcast, NASDAQ, Toronto Stock Exchange, Telecommunications, Mass media, Finance

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021.

Key Points: 
  • Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021.
  • Speakers will include David McNally, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.
  • A link to the live audio webcast will be made available on the "Investor Relations" section of the Companys website, www.titanmedicalinc.com .
  • A webcast replay will be archived and accessible on the Companys website shortly after conclusion of the live audio webcast.

Catalent Achieves 97% Renewable Electricity Sourcing and Commits to Science-Based Target Initiative to Reduce Carbon Footprint

Retrieved on: 
Tuesday, August 3, 2021
Other Manufacturing, Environment, Medical devices, Alternative energy, Manufacturing, Energy, Biotechnology, General Health, Pharmaceutical, Health, Articles, Catalent, Gene therapy, Environmental issues, Climate change, Natural environment, Climate change policy

Catalent will purchase renewable energy certificates for all of its sites operating in North America, South America and Europe, as well as the majority of its Asia-based facilities.

Key Points: 
  • Catalent will purchase renewable energy certificates for all of its sites operating in North America, South America and Europe, as well as the majority of its Asia-based facilities.
  • Catalent also recently signed a letter of commitment with the Science-Based Target initiative (SBTi), joining a growing list of companies setting actionable, science-based, greenhouse gas emission reduction targets to limit global warming.
  • This commitment will include calculating and reducing direct and indirect emissions as the Company continues to evolve and grow.
  • If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Catalents expectations and projections.

Former Los Angeles County Sheriff Jim McDonnell Joins Rithem Life Sciences’ Strategic Advisory Board

Retrieved on: 
Tuesday, August 3, 2021
Medical devices, Health, Local government in California, Jim McDonnell, Los Angeles County Sheriff's Department, California, Los Angeles Police Department, Long Beach Police Department, Local government in the United States

Rithem Life Sciences, a Wilmington, Delaware-based medical device company and developer of safe and efficacious life-saving portable products, has announced that former Los Angeles County Sheriff Jim McDonnell has joined its Strategic Advisory Board.

Key Points: 
  • Rithem Life Sciences, a Wilmington, Delaware-based medical device company and developer of safe and efficacious life-saving portable products, has announced that former Los Angeles County Sheriff Jim McDonnell has joined its Strategic Advisory Board.
  • McDonnell joins the Strategic Advisory Board that includes Major General (US Army Ret.)
  • He is the first person to serve in senior executive leadership positions in the three largest policing agencies in Los Angeles County: the Los Angeles County Sheriffs Department (LASD), the Los Angeles Police Department (LAPD), and the Long Beach Police Department (LBPD).
  • At Rithem Life Sciences, we are committed to providing Jim the necessary resources to help him realize his long-time vision of providing defibrillators in police units across the country, said Dr. Philip Werthman, Executive Chairman of Rithem Life Sciences Board of Directors.